High-density lipoprotein coated medical devices and methods of treatment using the devices

Patent metadata

Field	Value
Publication number	US-9993583-B2
Application number	US-201514636818-A
Country	US
Kind code	B2
Filing date	Mar 3, 2015
Priority date	Jan 2, 2004
Publication date	Jun 12, 2018
Grant date	Jun 12, 2018

Abstract

Method are disclosed for local and systemic administration HDL, recombinant HDL or HDLm for the prevention, treatment, or amelioration of a vascular disorder, disease or occlusion such as restenosis or vulnerable plaque.

First claim

What is claimed is:

1. A stent comprising:
poly(3-hydroxyhexanoate), poly(4-hydroxyhexanoate), or a combination thereof; and
a high-density lipoprotein (HDL), a recombinant HDL, a high-density lipoprotein mimic (HDLm), or a combination thereof;
wherein the HDLm comprises a polypeptide moiety that mimics the structure of a domain of apoA-I, apoA-II, or AI/AII-HDL.

2. The stent of claim 1 , wherein the stent is a bioabsorbable polymeric stent.

3. The stent of claim 2 , wherein the high-density lipoprotein (HDL), the recombinant HDL, the high-density lipoprotein mimic (HDLm), or the combination thereof is incorporated in the body of the stent.

4. The stent of claim 2 , wherein the stent comprises a polymeric coating and the high-density lipoprotein (HDL), the recombinant HDL, the high-density lipoprotein mimic (HDLm), or the combination thereof is incorporated in the coating.

5. The stent of claim 1 , wherein the stent comprises a polymeric coating comprising a polymer, the polymer comprising one or more hydrophobic biocompatible polymers, one or more hydrophilic biocompatible polymers, one or more biocompatible polymers having at least one hydrophilic component, or a combination thereof such that the high-density lipoprotein (HDL), the recombinant HDL, the high-density lipoprotein mimic (HDLm), or the combination thereof is incorporated in the coating.

6. The stent of claim 1 , wherein the stent comprises a coating, the coating comprising one or more reservoir regions, at least one reservoir region comprising the high-density lipoprotein (HDL), the recombinant HDL, the high-density lipoprotein mimic (HDLm), or the combination thereof incorporated therein, and a topcoat region over the at least one reservoir region.

7. The stent of claim 6 , wherein the coating additionally comprises a primer region beneath the reservoir region(s).

8. The stent of claim 1 , wherein the stent additionally comprises one or more drugs.

9. The stent of claim 8 , wherein at least one of the one or more drugs is everolimus, zotarolimus, paclitaxel, docetaxel, rapamycin, or a combination thereof.

10. The stent of claim 1 , wherein the stent further comprises a biobeneficial material, and the biobeneficial material comprises one or more polyethers; poly(ethylene glycol); one or more copoly(ether-esters); PEO/PLA; one or more polyalkylene oxides; poly(ethylene oxide); poly(propylene oxide); one or more poly(ether esters); one or more polyalkylene oxalates; one or more polyphosphazenes; phosphorylcholine; choline; poly(aspirin); poly(styrene-isoprene-styrene)-PEG (SIS-PEG); polystyrene-PEG; polyisobutylene-PEG; polycaprolactone-PEG (PCL-PEG); PLA-PEG; poly(methyl methacrylate)-PEG (PMMA-PEG); polydimethylsiloxane-co-PEG (PDMS-PEG); poly(vinylidene fluoride)-PEG (PVDF-PEG); one or more polypropylene oxide-co-polyethylene glycol surfactants; one or more poly(ethylene glycol)-block-poly(butyleneterephthalate)-block-poly(ethylene glycol) polymers; poly(tetramethylene glycol); one or more biomolecules; fibrin; fibrinogen; cellulose; starch; collagen; dextran; dextrin; hyaluronic acid; one or more fragments of hyaluronic acid; heparin; one or more fragments of heparin; glycosaminoglycan (GAG); one or more polysaccharides; elastin; chitosan; alginate; one or more silicones; or a combination thereof.

11. A method of treating a patient suffering from one or more medical conditions comprising implanting a stent in the patient, the stent comprising:
poly(3-hydroxyhexanoate), poly(4-hydroxyhexanoate), or a combination thereof; and
a high-density lipoprotein (HDL), a recombinant HDL, a high-density lipoprotein mimic (HDLm), or a combination thereof;
wherein the HDLm comprises a polypeptide moiety that mimics the structure of a domain of apoA-I, apoA-II, or AI/AII-HDL; and
wherein at least one of the medical conditions is vulnerable plaque, restenosis, stenosis, atherosclerosis, thrombosis, hemorrhage, vascular dissection or perforation, vascular aneurysm, claudication, anastomotic proliferation for vein and artificial grafts, or a combination thereof.

12. The method of claim 11 , wherein the method additionally comprises local administration of a high-density lipoprotein (HDL), a recombinant HDL, a high-density lipoprotein mimic (HDLm), or a combination thereof.

13. The method of claim 12 , wherein the local administration is delivery by a catheter, a porous balloon, or both.

14. The method of claim 12 , wherein local administration is delivery by an implantable pump, an implant which is not a stent, direct injection, local topical administration, or a combination thereof.

15. The method of claim 11 , wherein the patient is a type I diabetic or a type II diabetic.

16. The method of claim 11 , wherein the stent is a bioabsorbable polymeric stent.

17. The method of claim 16 , wherein the high-density lipoprotein (HDL), the recombinant HDL, the high-density lipoprotein mimic (HDLm), or the combination thereof is incorporated in the body of the stent.

18. The method of claim 16 , wherein the stent comprises a polymeric coating and the high-density lipoprotein (HDL), the recombinant HDL, the high-density lipoprotein mimic (HDLm), or the combination thereof is incorporated in the coating.

19. The method of claim 11 , wherein the stent comprises a polymeric coating comprising a polymer, the polymer comprising one or more hydrophobic biocompatible polymers, one or more hydrophilic biocompatible polymers, one or more biocompatible polymers having at least one hydrophilic component, or a combination thereof such that the high-density lipoprotein (HDL), the recombinant HDL, the high-density lipoprotein mimic (HDLm), or the combination thereof is incorporated in the coating.

20. The method of claim 11 , wherein the stent comprises a coating, the coating comprising one or more reservoir regions, at least one reservoir region having the high-density lipoprotein (HDL), the recombinant HDL, the high-density lipoprotein mimic (HDLm), or the combination thereof incorporated therein, and a topcoat region over the at least one reservoir region.

21. The method of claim 20 , wherein the coating additionally comprises a primer region beneath the reservoir region(s).

22. The method of claim 11 , wherein the stent additionally comprises one or more drugs.

23. The method of claim 22 , wherein at least one of the one or more drugs is everolimus, zotarolimus, paclitaxel, docetaxel, rapamycin, or a combination thereof.

Assignees

• Abbott Cardiovascular Systems Inc
• Advanced Cardiovascular Systems Inc

Inventors

• Ding Ni

Classifications

• A61P7/04

  Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents · CPC title

• A61P7/02

  Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors · CPC title

• A61P9/00

  Drugs for disorders of the cardiovascular system · CPC title

• A61P9/10

  for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis · CPC title

• A61F2/82

  Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents (stent-grafts for tubular structures of the body other than blood vessels A61F2/04; stent-grafts for blood vessels A61F2/07) · CPC title